

Supplementary Tables have been published as submitted, and have not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Characteristics of 1980 melanoma patients according to sex and age.

	Men n=1033	Women n=947	p-value	Age ≤70 n=1203	Age >70 n=777	p-value
Age mean, years	65.3	61.8	<0.0001	53.9	78.9	na
Never smoker	371 (36%)	470 (50%)	<0.0001	515 (43%)	326 (42%)	<0.0001
Former	224 (22%)	77 (8%)		170 (14%)	131 (17%)	
Persistent	126 (12%)	91 (10%)		167 (14%)	50 (6%)	
Unknown	312 (30%)	309 (33%)		351 (30%)	270 (35%)	
BMI mean, kg/m ²	27.6	27.5	ns	27.9	27.0	0.001
ECOG 0	126 (27%)	118 (33%)	ns	196 (43%)	48 (13%)	<0.0001
ECOG 1	245 (53%)	183 (51%)		220 (49%)	208 (57%)	
ECOG ≥2	92 (20%)	57 (16%)		38 (8%)	111 (30%)	
Comorbidities 0	619 (60%)	632 (67%)	0.002	913 (76%)	338 (44%)	<0.0001
Comorbidities ≥1	414 (40%)	315 (33%)		290 (24%)	439 (56%)	
Stage I	534 (52%)	605 (64%)	<0.0001	770 (64%)	369 (48%)	<0.0001
Stage II	215 (21%)	165 (17%)		163 (14%)	217 (28%)	
Stage III	180 (17%)	119 (13%)		172 (14%)	127 (16%)	
Stage IV	104 (10%)	58 (6%)		98 (8%)	64 (8%)	

na=not applicable, ns=not significant

Table SII. Characteristics of 351 stage IV melanoma patients according to smoking status.

Smoking status	Never n=194	Former n=94	Persistent n=63	p-value
Women	100 (52%)	18 (19%)	12 (19%)	<0.0001
Mean age (range), years	65.0 (19-95)	67.9 (33-90)	61.5 (36-84)	0.17
Mean BMI, kg/m ²	27.6	28.7	25.8	0.08
Charlson comorbidity index 0	111 (57%)	48 (51%)	37 (59%)	0.54
Charlson comorbidity index ≥1	83 (43%)	46 (49%)	26 (41%)	
ECOG 0	48 (25%)	23 (24%)	8 (13%)	0.36
ECOG ≥1	146 (75%)	71 (76%)	55 (87%)	
BRAF mutation				
No	60 (54%)	25 (57%)	11 (38%)	0.24
Yes	52 (46%)	19 (43%)	18 (62%)	
Metastasis stage				
M1a (skin, subcutaneous, or lymph node metastases only)	81 (42%)	31 (33%)	23 (37%)	0.28
M1b (lung)	30 (16%)	25 (27%)	11 (18%)	
M1c (other non-CNS sites)	58 (30%)	26 (28%)	17 (27%)	
M1d (CNS involvement)	25 (13%)	11 (12%)	12 (19%)	
First-line treatment				
Immune checkpoint inhibitors	17 (9%)	8 (9%)	4 (6%)	0.85
BRAF±MEK inhibitors	30 (15%)	12 (13%)	9 (14%)	
Chemotherapy	49 (25%)	20 (21%)	19 (30%)	
Best supportive care only	98 (51%)	54 (57%)	31 (49%)	

CNS=central nervous system